Global Retirement Partners LLC Invests $982,000 in Vertex Pharmaceuticals Incorporated $VRTX

Global Retirement Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 2,205 shares of the pharmaceutical company’s stock, valued at approximately $982,000.

A number of other large investors have also bought and sold shares of VRTX. Jefferies Financial Group Inc. raised its holdings in shares of Vertex Pharmaceuticals by 77.7% during the second quarter. Jefferies Financial Group Inc. now owns 34,615 shares of the pharmaceutical company’s stock worth $15,411,000 after acquiring an additional 15,131 shares during the period. Prudential Financial Inc. increased its holdings in Vertex Pharmaceuticals by 6.7% during the 2nd quarter. Prudential Financial Inc. now owns 180,236 shares of the pharmaceutical company’s stock worth $80,241,000 after purchasing an additional 11,381 shares in the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Vertex Pharmaceuticals by 13.8% in the 2nd quarter. Coldstream Capital Management Inc. now owns 5,874 shares of the pharmaceutical company’s stock valued at $2,615,000 after purchasing an additional 711 shares during the period. Vestor Capital LLC lifted its holdings in shares of Vertex Pharmaceuticals by 180.3% in the second quarter. Vestor Capital LLC now owns 970 shares of the pharmaceutical company’s stock valued at $432,000 after purchasing an additional 624 shares in the last quarter. Finally, Cynosure Group LLC boosted its position in shares of Vertex Pharmaceuticals by 30.6% during the second quarter. Cynosure Group LLC now owns 918 shares of the pharmaceutical company’s stock worth $409,000 after buying an additional 215 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 0.5%

NASDAQ:VRTX opened at $432.17 on Friday. The stock has a market capitalization of $109.65 billion, a PE ratio of 30.89 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The firm has a fifty day simple moving average of $414.58 and a 200 day simple moving average of $425.09.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the company posted $4.38 earnings per share. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VRTX. Morgan Stanley dropped their target price on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. Canaccord Genuity Group cut their price objective on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Barclays increased their target price on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Finally, Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $491.95.

Insider Transactions at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 53,604 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $440.72, for a total transaction of $23,624,354.88. Following the completion of the transaction, the chairman owned 24,026 shares in the company, valued at approximately $10,588,738.72. This trade represents a 69.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.